The new CEOs in bio­phar­ma are join­ing the big play­ers at the bil­lion-dol­lar chip ta­ble

Call it new CEO syn­drome.

Every time a new CEO takes over at a bio­phar­ma com­pa­ny of some size, the in­stinc­tive re­sponse is to look for some deal or deals that will help set the tone for the new leader, prefer­ably one that is pre­dic­tive of a bold — but not reck­less — de­sign on fu­ture growth.

So per­haps it was no great sur­prise to see No­vo Nordisk fig­ure in­to the lat­est round of buy­out ru­mors — this time fo­cused on Glob­al Blood Ther­a­peu­tics and its lead drug for sick­le cell dis­ease. No­vo’s new CEO, Lars Fruer­gaard Jor­gensen, per­haps telling­ly wouldn’t com­ment on that to Reuters. But he had plen­ty to say about his in­ter­est in deal­mak­ing.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.